FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial. PMID 39106066 · JAMA Netw Open · 2024-Aug-01 The study is a Phase 3 randomized trial with a drug intervention in oncology, but it does not meet the requirement for a primary or key secondary time-to-event efficacy endpoint. The primary endpoint (complete response) is a binary categorical outcome, not a time-to-event measure like OS, PFS, or TTP analyzed via Kaplan-Meier or Hazard Ratio. The study focuses on preventing chemotherapy-induced nausea and vomiting, which is a supportive care endpoint, not a direct measure of tumor-related efficacy. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. PMID 39099199 · Cancer Res Commun · 2024-Aug-01 The record is a secondary analysis/meta-research study of secondary endpoint utilization in oncology trials, not an original report of a single randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial. PMID 39090600 · BMC Cancer · 2024-Aug-01 This is a protocol-only publication for a randomized trial. While it meets criteria for oncology, human, randomized, and includes a drug intervention, it is not a results report. Furthermore, the primary endpoint (time to first biliary event) is not a standard oncology efficacy endpoint (OS, PFS, DFS, etc.) required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. PMID 39076107 · Cancer Res Commun · 2024-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous electrical acupoint stimulation for alleviating pain in patients with advanced pancreatic cancer. PMID 38935575 · J Cancer Res Ther · 2024-Aug-01 The study is a randomized trial in advanced pancreatic cancer, but it is not a Phase III/IIIb or Phase II/III trial, its primary endpoint is pain score (not time-to-event), and the intervention is non-drug (acupoint stimulation). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. PMID 38900452 · JAMA Oncol · 2024-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial. PMID 38900416 · JAMA Otolaryngol Head Neck Surg · 2024-Aug-01 The study is a Phase III randomized controlled trial with a drug/radiopharmaceutical intervention and reports primary results, but it is not an oncology study (it addresses primary hyperparathyroidism, a non-malignant endocrine condition) and its primary endpoint is a dichotomous outcome (successful minimally invasive parathyroidectomy combined with normocalcemia), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Erratum: Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). PMID 38885462 · J Clin Oncol · 2024-Aug-01 The record is a published erratum for a Phase III trial, not a primary result report. The empty abstract prevents confirmation of any time-to-event efficacy endpoint (Kaplan-Meier, HR, OS, PFS, etc.). Therefore, it does not meet the criteria for an original result report of a randomized trial with a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies. PMID 38871390 · J Nucl Med · 2024-Aug-01 The study is a diagnostic reproducibility analysis of 18F-flotufolastat PET/CT image interpretation from two phase 3 prostate cancer studies. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS) for a drug intervention in a randomized trial. The intervention is a diagnostic imaging agent, and the outcomes are inter/intrareader agreement metrics, not clinical efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. PMID 38865678 · J Clin Oncol · 2024-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient Navigation for Lung Cancer Screening at a Health Care for the Homeless Program: A Randomized Clinical Trial. PMID 38856994 · JAMA Intern Med · 2024-Aug-01 This is a randomized clinical trial in an oncology population (lung cancer screening) but does not meet the core eligibility criteria: 1) it is not a Phase III/IIIb or Phase II/III trial (no drug phase specified; it is a pragmatic behavioral trial), 2) it does not involve a drug-containing intervention (the intervention is patient navigation), and 3) the primary outcome is not a time-to-event efficacy endpoint (receipt of screening at 6 months is a binary outcome, not OS, PFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. PMID 38809262 · Clin Cancer Res · 2024-Aug-01 The record describes an FDA Approval Summary for fruquintinib, which is a secondary source summarizing the pivotal trial (FRESCO-2). While it reports formal efficacy results (HR, median OS) from a randomized, placebo-controlled trial, the report itself is not the original primary trial publication. Furthermore, the trial phase (Phase III) is not explicitly stated in the provided text, only implying it via the context of a pivotal registration trial. Therefore, the original report criterion is not met, and the phase criterion cannot be definitively established from the given text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone. PMID 38794915 · Hum Reprod · 2024-Aug-01 The study is an original report embedded in a randomized Phase 3 oncology trial with a drug intervention. However, the primary endpoint is not a time-to-event efficacy outcome (like OS or PFS). Instead, it evaluates a biomarker (serum AMH) for gonadotoxicity, which is a secondary/safety endpoint, not a primary/key secondary efficacy endpoint. Therefore, it does not meet the required criteria for Kaplan-Meier digitization. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029). PMID 38718190 · Anticancer Drugs · 2024-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. PMID 38717861 · Blood · 2024-Aug-01 This is a secondary analysis report of a Phase 3 randomized trial. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results, it is excluded because the primary focus and presented results are on a quality-of-life endpoint, not the required time-to-event efficacy endpoint (e.g., OS, PFS). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Totally laparoscopic versus laparoscopy-assisted distal gastrectomy: the KLASS-07: a randomized controlled trial. PMID 38716987 · Int J Surg · 2024-Aug-01 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17. PMID 38656931 · J Natl Cancer Inst · 2024-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study. PMID 38603641 · J Clin Oncol · 2024-Aug-01 The study is embedded in a Phase III oncology trial but evaluates the neurocognitive impact of propofol exposure (an anesthesia agent) as a risk factor. It is not a report of the trial's primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The intervention studied (propofol exposure) is not a therapeutic drug intervention for the malignancy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. PMID 38581694 · Cancer · 2024-Aug-01 The trial meets criteria for oncology, human, randomized, phase 3, and original result. However, it is ineligible because (1) the intervention is non-drug-only (radiation therapy only) and (2) the primary endpoint is not a time-to-event efficacy endpoint; it is a pain response rate at a fixed time point. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study. PMID 38356458 · Haematologica · 2024-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Real-time ultrasound elastography in the diagnosis of newly identified thyroid nodules in adults: the ElaTION RCT. PMID 39252469 · Health Technol Assess · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT. PMID 39246267 · Health Technol Assess · 2024-Aug The study is an oncology randomized trial in humans, but it does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial (it is a feasibility/intermediate-stage trial), it does not evaluate a drug-containing intervention (it compares diagnostic staging pathways), and its primary endpoint is a process measure (time to correct treatment initiation), not a clinical efficacy time-to-event endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). PMID 39162634 · Radiology · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial. PMID 39161543 · EClinicalMedicine · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Increasing coverage in cervical and colorectal cancer screening by leveraging attendance at breast cancer screening: A cluster-randomised, crossover trial. PMID 39137185 · PLoS Med · 2024-Aug The record is a human oncology randomized trial reporting primary results, but it fails two mandatory criteria: (1) The intervention is not drug-containing (it is a screening logistics/self-sampling intervention). (2) The primary endpoint is screening coverage/participation, a proportion, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. PMID 39135303 · Cancer Med · 2024-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Barriers and proposed solutions to at-home colorectal cancer screening tests in medically underserved health centers across three US regions to inform a randomized trial. PMID 39118261 · Cancer Med · 2024-Aug Qualitative study to inform the design of a future pragmatic trial; does not report results of a randomized drug intervention trial with time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394. PMID 39114760 · Liver Cancer · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Robotic-assisted versus video-assisted lobectomy for resectable non-small-cell lung cancer: the RVlob randomized controlled trial. PMID 39105193 · EClinicalMedicine · 2024-Aug Eligible record for oncology, randomized, human trial with time-to-event primary endpoint. Excluded because the intervention is surgical (robotic-assisted vs. video-assisted lobectomy) and does not meet the 'drug-containing intervention' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. PMID 39068945 · Lancet Oncol · 2024-Aug The record describes a randomized, drug-interventional trial in a human oncology setting with a primary time-to-event endpoint (PFS) and a final, original result. While the explicit Phase label is not in the title or abstract, the trial design (multi-arm, randomized, powered for a primary endpoint with formal statistical testing, completed and final) is consistent with a definitive Phase II/III or Phase III trial. The metadata does not provide evidence to exclude it based on the required criteria. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations. PMID 39059061 · ESMO Open · 2024-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. PMID 39029483 · Lancet Oncol · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Treatment with Celecoxib after Collagenase Injection for Dupuytren Contracture: A Double-Blind Randomised Controlled Trial. PMID 39005176 · J Hand Surg Asian Pac Vol · 2024-Aug 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial. PMID 38987116 · Lancet Digit Health · 2024-Aug The record is a secondary analysis of biomarker data from a randomized trial cohort. While it is oncology, human, randomized, and time-to-event, it does not meet the core criterion of being a primary report of a drug intervention in a Phase III/IIIb or Phase II/III trial. The abstract does not specify the trial's phase or confirm a drug intervention as the focus of the original trial being analyzed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Oral Hygiene With Neutral Electrolyzed Water and Systemic Therapy Increases Gastric Helicobacter pylori Eradication and Reduces Recurrence. PMID 38973212 · Clin Exp Dent Res · 2024-Aug Study is a randomized, drug-containing intervention trial, but it is not an oncology trial; its focus is on eradication of Helicobacter pylori infection and prevention of recurrence, which are not considered human malignant neoplasms. The primary endpoint is eradication rate (a binary outcome), not a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. PMID 38958846 · Adv Ther · 2024-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi-centre factorial randomized trial. PMID 38887915 · J Cachexia Sarcopenia Muscle · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term statin use and risk of cancers: a target trial emulation study. PMID 38880437 · J Clin Epidemiol · 2024-Aug The record describes an observational study emulating target trials using real-world data to assess the association between long-term statin use and cancer incidence. It is not an original report of a randomized Phase III/IIIb or Phase II/III clinical trial with a drug intervention for cancer. The study is non-interventional and its primary endpoint is cancer incidence (a safety/outcome measure), not a time-to-event efficacy endpoint (like OS, PFS, etc.) from a randomized trial evaluating a cancer drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. PMID 38870977 · Lancet Gastroenterol Hepatol · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. PMID 38867615 · Br J Haematol · 2024-Aug The record describes a Phase III randomized trial in follicular lymphoma with drug interventions, but the primary analysis is immunogenicity of COVID-19 vaccines (antibody and T-cell responses), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, nor Kaplan-Meier or HR for such endpoints. Therefore, it does not meet the time-to-event efficacy requirement. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. PMID 38861580 · Expert Rev Anticancer Ther · 2024-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| How long does it take to read a mammogram? Investigating the reading time of digital breast tomosynthesis and digital mammography. PMID 38852330 · Eur J Radiol · 2024-Aug The study is a randomized trial in oncology (breast cancer screening) but is excluded because it lacks a drug intervention and a time-to-event efficacy endpoint. It evaluates imaging modalities (digital breast tomography vs. digital mammography) with reading time as the primary outcome, not a survival or progression endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of inadequate bowel cleansing in sigmoidoscopy screening. PMID 38850200 · Scand J Gastroenterol · 2024-Aug The record describes a randomized trial on colorectal cancer screening with a primary endpoint of adenoma detection rate (a diagnostic/procedural outcome), not a time-to-event efficacy endpoint (e.g., OS, PFS). No drug-containing intervention is identified; the focus is on the procedural aspect of bowel cleansing quality for sigmoidoscopy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lower incidence of vaginal cancer after cervical human papillomavirus screening - long-term follow-up of Finnish randomized screening trial. PMID 38849059 · Prev Med · 2024-Aug The record is a randomized trial in oncology (screening for vaginal/vulvar cancer) but does not meet the eligibility criteria because it is not a trial of a drug-containing intervention, and its primary endpoints are incidence and mortality rate ratios (IRR/MRR), not time-to-event efficacy endpoints (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analyses. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial. PMID 38842053 · Minerva Urol Nephrol · 2024-Aug The record describes a randomized, oncology, human trial with a drug intervention and a time-to-event endpoint (Disease Free Interval). However, it is an interim analysis of a trial where the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the abstract or metadata. Therefore, it does not meet the criterion for being a definitive Phase III/IIIb or Phase II/III trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Increasing Uptake of Lung Cancer Screening Among Emergency Department Patients: A Pilot Study. PMID 38839453 · J Emerg Med · 2024-Aug The study is an oncology, human, randomized, original-result trial, but it is a pilot/feasibility study (not Phase III), does not involve a drug-containing intervention (text message and referral are non-drug), and does not report a time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma. PMID 38838446 · Eur J Cancer · 2024-Aug The record is a safety-only analysis of pooled Phase III trials. While it meets criteria for oncology, human, randomized, phase 3, and drug intervention, it lacks a primary/key secondary time-to-event efficacy endpoint. The abstract focuses solely on adverse event summaries, not efficacy outcomes like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over. PMID 38821039 · Gynecol Oncol · 2024-Aug This is a secondary biomarker analysis focusing on homologous recombination deficiency rates in a subgroup (patients ≥70 years) from the Phase III VELIA trial. It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) for a drug intervention, but rather characterizes a biological marker's prevalence. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221. PMID 38814343 · Cancer Chemother Pharmacol · 2024-Aug The record describes a secondary/biomarker analysis from a Phase III randomized trial in early-stage breast cancer. While it meets criteria for oncology, human, randomized, Phase III, and drug intervention, the primary endpoint is not a time-to-event efficacy outcome. The study investigates the association between pre-treatment amino acid levels and the risk/severity of chemotherapy-induced peripheral neuropathy, which is a safety/toxicity endpoint, not a key efficacy endpoint like OS, PFS, or DFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. PMID 38781786 · Clin Genitourin Cancer · 2024-Aug The record explicitly describes a 'non-randomized trial'. This excludes it from the required randomized controlled trial cohort. The trial phase is not established as Phase III/IIIb or Phase II/III in the provided text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |